Status:
COMPLETED
L-arginine and Asymmetric Dimethylarginine (ADMA) and Lifestyle Protocols
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Collaborating Sponsors:
Wolfson Medical Center
Conditions:
Diabetes Mellitus, Type 2
Obesity
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
Low serum L-arginine (Arg) and high asymmetric dimethylarginine (ADMA) can predict microvascular complications in type 2 diabetes (T2DM). The investigators examined whether or not Arg and ADMA are aff...
Detailed Description
The investigators tested the effects on serum Arg and ADMA of a) a single load of ingested dextrose, protein, fat or alcohol, each consumed within 10 minutes; b) a single episode of physical exercise;...
Eligibility Criteria
Inclusion
- obese and/ or T2DM subjects
Exclusion
- type 1 diabetes
- insulin-treated T2DM
- active coronary disease (recent \[≤ 6months\] myocardial infarction, unstable angina, recent coronary catheterization, or coronary bypass grafting
- individuals with significant impairment in liver enzymes (≥ 2.5 the upper limit of the normal range)
- serum creatinine higher than 1.5mg%
- known malabsorption, alcoholism or illicit use of drugs
- abnormal thyroid function tests
- concomitant or recent use of glucocorticoids
- uncertain mental state (to avoid invalid informed consent or lack of compliance).
Key Trial Info
Start Date :
December 5 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 10 2008
Estimated Enrollment :
243 Patients enrolled
Trial Details
Trial ID
NCT04406402
Start Date
December 5 2006
End Date
December 10 2008
Last Update
June 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Diabetes Unit, E. Wolfson Medical Center
Holon, Israel, 5822012